GlassScriptPhysician profile
Craig A Thurm
NPI 1174585681
$603,840.30
in general payments reported to CMS, 2019-2025
19 companies · $41K in 2025
The $41K reported for 2025 was more than what 97% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234K · 2020: $73K · 2021: $73K · 2022: $51K · 2023: $57K · 2024: $74K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $143K · Travel and Lodging: $16K · Consulting Fee: $9,828 · Food and Beverage: $3,749 · Education: $96.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $142,623.35 |
| Travel and Lodging | $15,556.20 |
| Consulting Fee | $9,828.00 |
| Food and Beverage | $3,748.65 |
| Education | $96.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $157,222.53 | 2019-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $151,780.59 | 2019-2025 | Dupixent |
| Genzyme Corporation | $124,503.19 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $46,167.31 | 2019-2021 | |
| Mylan Specialty L.P. | $46,060.93 | 2019-2024 | Yupelri, Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,044.73 | 2019-2022 | |
| Viatris Specialty LLC | $18,676.89 | 2025 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $15,494.90 | 2019-2023 | Tezspire |
| Sunovion Pharmaceuticals INC. | $12,617.28 | 2019 | |
| Insmed, INC. | $4,437.62 | 2019-2020 | |
| Shionogi INC | $800.00 | 2021 | |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Olympus Corporation of The Americas | $332.56 | 2019 | |
| Advanced Respiratory, INC | $42.16 | 2020 | |
| Paratek Pharmaceuticals, INC. | $39.95 | 2023 | Nuzyra |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $19.66 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Thurm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.